News tagged with erbitux
Cetuximab (IMC-C225—marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.
Other May 14, 2013 | not rated yet | 0
Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
Other Mar 07, 2013 | 2 / 5 (1) | 0
Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center, published in the January issue ...
Cancer Jan 14, 2013 | 5 / 5 (2) | 0 |
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.
Cancer Sep 18, 2012 | not rated yet | 0
(HealthDay) -- A new genetic test to help doctors determine if the drug Erbitux would be an effective treatment for certain colorectal cancer patients has been approved by the U.S. Food and Drug Administration.
Cancer Jul 09, 2012 | not rated yet | 0
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.
Cancer Jul 05, 2012 | not rated yet | 0
Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical ...
Cancer Oct 11, 2011 | not rated yet | 0
A team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can ...
Cancer Jul 06, 2011 | not rated yet | 0 |
High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented ...
Cancer Jul 05, 2011 | not rated yet | 0